Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spago Nanomedical ABFRA:7UX -6.25%34 EBIT per Share is €-0.00 as of Mar. 2026. GuruFocus rates FRA:7UX with a GF Score™ of 34/100. The stock has 4 warning signs investors should review. Among 1,171 Biotechnology companies, Spago Nanomedical AB ranks better than 82.32% on this metric.
Spago Nanomedical AB's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.00.
During the past 3 years, the average EBIT per Share Growth Rate was 44.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 35.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 16.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Spago Nanomedical AB's EBIT per Share or its related term are showing as below:
FRA:7UX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -25.2 Med: 13.9 Max: 47.6
Current: 44.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Spago Nanomedical AB was 47.60% per year. The lowest was -25.20% per year. And the median was 13.90% per year.
FRA:7UX's 3-Year EBIT Growth Rate is ranked better than 82.32% of 1171
companies
in the Biotechnology industry
Industry Median: 15.5
vs FRA:7UX: 44.60
Spago Nanomedical AB (FRA:7UX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Spago Nanomedical AB EBIT per Share Related Terms
Spago Nanomedical AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Spago Nanomedical AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spago Nanomedical AB (FRA:7UX) has a EBIT per Share of €-0.00 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Spago Nanomedical AB and its competitors. According to the industry distribution chart, Spago Nanomedical AB ranks #207 out of 1171 companies in the Biotechnology industry, placing it in the top 17.7%.
Is Spago Nanomedical AB's EBIT per Share too high?
Spago Nanomedical AB's current EBIT per Share is €-0.00. Based on the distribution chart, Spago Nanomedical AB ranks #207 out of 1171 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Spago Nanomedical AB has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Spago Nanomedical AB's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Spago Nanomedical AB ranks #207 out of 1171 companies for EBIT per Share. This places Spago Nanomedical AB in the top 18% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,171 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Spago Nanomedical AB and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spago Nanomedical AB's current EBIT per Share is €-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spago Nanomedical AB stock overvalued right now?
Spago Nanomedical AB (FRA:7UX) has a current EBIT per Share of €-0.00. The current EBIT per Share is €-0.00. Spago Nanomedical AB's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Spago Nanomedical AB (FRA:7UX), the current EBIT per Share is €-0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
34GF Score
Get the complete analysis for FRA:7UX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7UX has been successfully added to your 
